News

Cardiff Oncology Stock: Market Dismisses Onvansertib’s Potential In Colorectal Cancer

1 Mins read

This article was written by

Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative companies developing breakthrough therapies and/or pharmaceuticals with catalysts for potential acquisitions.
He is the leader of the investing group Compounding Healthcare. Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRDF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read the full article here

Related posts
News

Generation Investment Management Senior Partner Letter

9 Mins read
Dear fellow investors The year 2025 was marked by escalating ‘climate realism’ – a new and cynical term for climate denialism –…
News

Top 25 High-Yield Dividend Stocks For April 2026

1 Mins read
This article was written by Follow I have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting….
News

2 Closed-End Funds Worth A 'Buy'

1 Mins read
This article was written by Follow Nick Ackerman is a former financial advisor using his experience to provide coverage on closed-end funds…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *